Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AEZS Aeterna Zentaris	$2.70 -2.9%	$3.58	$3.96 ▼ $12.00	$10.26M	1.55	7,305 shs	5,993 shs
HCWB HCW Biologics	$3.45 +4.2%	$4.37	$2.77 ▼ $100.80	$4.97M	0.66	363,658 shs	16,833 shs
KTTA Pasithea Therapeutics	$0.72 +0.7%	$0.72	$0.65 ▼ $7.50	$5.34M	0.26	2.88 million shs	33,150 shs
SHPH Shuttle Pharmaceuticals	$3.44 +1.8%	$3.72	$3.00 ▼ $82.50	$1.51M	-1.08	127,097 shs	28,258 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AEZS Aeterna Zentaris	+5.70%	-20.57%	-33.65%	-23.07%	-52.64%
HCWB HCW Biologics	-2.65%	-23.73%	-23.38%	-60.45%	-80.72%
KTTA Pasithea Therapeutics	+0.98%	+1.34%	-1.10%	-22.20%	-85.10%
SHPH Shuttle Pharmaceuticals	+2.11%	-3.43%	-12.89%	-22.30%	-93.17%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AEZS Aeterna Zentaris	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
HCWB HCW Biologics	2.1845 of 5 stars	3.5	3.0	0.0	0.0	1.5	1.7	0.0
KTTA Pasithea Therapeutics	1.2416 of 5 stars	0.0	5.0	0.0	0.0	2.9	0.0	0.6
SHPH Shuttle Pharmaceuticals	1.0149 of 5 stars	0.0	5.0	0.0	0.0	1.3	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AEZS Aeterna Zentaris	0.00	N/A	N/A	N/A
HCWB HCW Biologics	3.00	Buy	$35.00	914.49% Upside
KTTA Pasithea Therapeutics	0.00	N/A	N/A	N/A
SHPH Shuttle Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest SHPH, KTTA, AEZS, and HCWB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
5/29/2025	HCWB HCW Biologics	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$120.00 ➝ $35.00

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AEZS Aeterna Zentaris	$2.37M	2.04	N/A	N/A	$14.99 per share	0.18
HCWB HCW Biologics	$2.57M	1.93	N/A	N/A	($0.04) per share	-86.25
KTTA Pasithea Therapeutics	N/A	N/A	N/A	N/A	$2.04 per share	N/A
SHPH Shuttle Pharmaceuticals	N/A	N/A	N/A	N/A	$8.21 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AEZS Aeterna Zentaris	-$16.55M	-$14.86	N/A	∞	N/A	-760.32%	-83.45%	-45.76%	N/A
HCWB HCW Biologics	-$30.02M	-$14.04	N/A	∞	N/A	-1,368.55%	N/A	-40.72%	N/A
KTTA Pasithea Therapeutics	-$13.90M	-$7.55	N/A	∞	N/A	N/A	-88.60%	-81.10%	N/A
SHPH Shuttle Pharmaceuticals	-$9.15M	-$4.15	N/A	∞	N/A	N/A	-772.76%	-347.06%	9/2/2025 (Estimated)

Latest SHPH, KTTA, AEZS, and HCWB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/18/2025	Q2 2025	HCWB HCW Biologics	$1.80	-$6.79	-$8.59	-$6.79	$7.00 million	$0.01 million
8/14/2025	Q2 2025	KTTA Pasithea Therapeutics	N/A	-$0.66	N/A	-$0.66	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AEZS Aeterna Zentaris	N/A	N/A	N/A	N/A	N/A
HCWB HCW Biologics	N/A	N/A	N/A	N/A	N/A
KTTA Pasithea Therapeutics	N/A	N/A	N/A	N/A	N/A
SHPH Shuttle Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AEZS Aeterna Zentaris	N/A	5.94	5.93
HCWB HCW Biologics	N/A	0.11	0.07
KTTA Pasithea Therapeutics	N/A	4.97	3.84
SHPH Shuttle Pharmaceuticals	N/A	3.07	3.07

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AEZS Aeterna Zentaris	0.73%
HCWB HCW Biologics	2.96%
KTTA Pasithea Therapeutics	23.92%
SHPH Shuttle Pharmaceuticals	4.58%

Insider Ownership

Company	Insider Ownership
AEZS Aeterna Zentaris	0.10%
HCWB HCW Biologics	42.70%
KTTA Pasithea Therapeutics	2.70%
SHPH Shuttle Pharmaceuticals	12.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AEZS Aeterna Zentaris	20	1.79 million	1.79 million	No Data
HCWB HCW Biologics	40	1.44 million	825,000	Not Optionable
KTTA Pasithea Therapeutics	3	7.44 million	7.24 million	Not Optionable
SHPH Shuttle Pharmaceuticals	5	440,000	384,000	Not Optionable

SHPH, KTTA, AEZS, and HCWB Headlines

Recent News About These Companies

Shuttle Pharmaceuticals Holdings, Inc.: Shuttle Pharma Provides Second Quarter 2025 Corporate Update

August 16, 2025 | finanznachrichten.de

Shuttle Pharma Provides Second Quarter 2025 Corporate Update

August 14, 2025 | globenewswire.com

Shuttle Pharmaceuticals COO Resigns Amid Leadership Changes

July 30, 2025 | tipranks.com

Shuttle Pharmaceuticals Inc News (SHPH) - Investing.com

July 2, 2025 | investing.com

SHPH - Shuttle Pharmaceuticals Holdings Inc Key Metrics | Morningstar

June 28, 2025 | morningstar.comM

Shuttle Pharmaceuticals Announces Closing of $4.25 Million Private Placement Priced At-the-Market - Morningstar

June 26, 2025 | morningstar.comM

SHPH - Shuttle Pharmaceuticals Holdings Inc News | Morningstar

June 26, 2025 | morningstar.comM

Shuttle Pharmaceuticals Secures $4.25M in Private Placement

June 26, 2025 | msn.com

Shuttle Pharmaceuticals Announces Closing of $4.25 Million Private Placement Priced At-the-Market

June 24, 2025 | globenewswire.com

Shuttle Pharmaceuticals Announces Pricing of $4.25 Million Private Placement Priced At-the-Market

June 20, 2025 | globenewswire.com

Shuttle Pharmaceuticals Holdings Inc trading halted, news pending

June 14, 2025 | msn.com

Shuttle Pharmaceuticals says reverse stock split to become effective June 16

June 13, 2025 | finance.yahoo.com

Shuttle Pharma Announces Reverse Stock Split will Become Effective on June 16, 2025, at 12:01 a.m., Eastern Time

June 12, 2025 | globenewswire.com

Shuttle Pharmaceuticals Holdings, Inc. Proposes 25-for-1 Reverse Stock Split to Comply with Nasdaq Requirements

June 12, 2025 | quiverquant.comQ

Shuttle Pharma Announces Proposed Reverse Stock Split as Part of Strategic Nasdaq Compliance Initiative

June 12, 2025 | globenewswire.com

Shuttle Pharma Appoints George Scorsis Chairman of the Board of Directors

June 4, 2025 | globenewswire.com

Shuttle Pharmaceuticals slashes exec salaries by 70% as it fights to preserve cash

May 29, 2025 | bizjournals.com

Shuttle Pharmaceuticals Holdings, Inc.: Shuttle Pharma Provides Corporate Update

May 16, 2025 | finanznachrichten.de

Shuttle Pharma Provides Corporate Update

May 15, 2025 | globenewswire.com

Shuttle Pharma FDA Orphan-Drug Nears Patient Enrollment Milestone for Phase 2 Clinical Trial

May 8, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SHPH, KTTA, AEZS, and HCWB Company Descriptions

Aeterna Zentaris NASDAQ:AEZS

$2.70 -0.08 (-2.88%)

As of 08/21/2025

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.

HCW Biologics NASDAQ:HCWB

$3.45 +0.14 (+4.23%)

Closing price 03:59 PM Eastern

Extended Trading

$3.46 +0.01 (+0.43%)

As of 06:13 PM Eastern

HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.

Pasithea Therapeutics NASDAQ:KTTA

$0.72 +0.01 (+0.70%)

Closing price 03:54 PM Eastern

Extended Trading

$0.70 -0.02 (-3.08%)

As of 06:36 PM Eastern

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.

Shuttle Pharmaceuticals NASDAQ:SHPH

$3.44 +0.06 (+1.78%)

Closing price 03:49 PM Eastern

Extended Trading

$3.39 -0.05 (-1.48%)

As of 06:37 PM Eastern

Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers . The company is based in Gaithersburg, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time